RenovoRx expands commercial footprint to 13 cancer centers

RenovoRx (NASDAQ:RNXT) is expanding the commercial footprint of its FDA-cleared RenovoCath device, now adopted by 13 cancer centers, four of which are actively using and reordering, contributing to Q1 2025 revenue of $200,000 that exceeded internal expectations. Despite rapid cash burn, the company maintains strong liquidity and is strategically bolstering its sales efforts while advancing its Phase III TIGeR-PaC trial, which could further expand its customer base. This progress has led Ascendiant Capital to raise its price target to $11.50 with a Buy rating, signaling increasing analyst confidence in RNXT's growth prospects.

Analysis

RenovoRx, Inc. (NASDAQ:RNXT) is demonstrating initial commercial traction for its FDA-cleared RenovoCath device, having expanded its user base to 13 cancer centers from five in the previous quarter. Critically, four of these centers are now active users placing repeat orders, which contributed to first-quarter 2025 revenue of $200,000, surpassing the company's internal forecasts. This commercial progress is supported by a strong balance sheet characterized by more cash than debt and a high liquidity ratio of 9.07x, although this is offset by a noted rapid cash burn. Future growth is predicated on two key catalysts: the strategic hire of a Senior Director of Sales with deep interventional oncology experience to accelerate market penetration, and the potential conversion of 18 cancer centers participating in its ongoing Phase III TIGeR-PaC clinical trial into commercial customers. The trial, evaluating a drug-device combination with Orphan Drug Designation, is expected to complete enrollment late this year or early next, representing a significant near-term inflection point. Analyst sentiment is positive, with Ascendiant Capital reaffirming a Buy rating and raising its price target to $11.50, signaling confidence in the company's growth trajectory.

Key Decisions for Investors

• Investors should monitor the rate of new cancer center adoption and the conversion of existing trial sites into commercial customers as primary indicators of sustained revenue growth.
• Carefully track the company's quarterly cash burn rate against its current liquidity, as managing this will be critical to funding operations through to key clinical and commercial milestones.
• The completion of the Phase III TIGeR-PaC trial enrollment and subsequent data release represent a significant near-term catalyst that could substantially impact the company's valuation.
• Consider the Ascendiant Capital price target of $11.50 as an external benchmark for potential upside, but weigh it against the execution risks inherent in a small-cap medical device company's commercial ramp-up.